Nivolumab vs Spironolactone
Nivolumab vs Spironolactone: Overview
This comparison examines the pharmacological differences between Nivolumab and Spironolactone.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Spironolactone: Mineralocorticoid receptor antagonist.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Spironolactone — 1.4 hours.
Chemical Properties
Molecular Formula: Spironolactone — C24H32O4S.
Molecular Weight: Spironolactone — 416.5740 g/mol.
Type: Nivolumab — Antibody; Spironolactone — Small molecule.